Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Recurrence 1 Rectal Neoplasms 1 Neuroendocrine Tumors 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1 Leukemia, Myeloid, Acute 1 Leukemia, Erythroblastic, Acute 1 Hodgkin Disease 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Cyclophosphamide 30 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 21 Prednisone 20 Etoposide 20 Vincristine 16 Whole-Body Irradiation 15 Doxorubicin 15 fludarabine phosphate 14 Peripheral Blood Stem Cell Transplantation 14 romidepsin 13 Mycophenolic Acid 12 Lenalidomide 12 Gemcitabine 12 Cyclosporine 10 Azacitidine 10 Brentuximab Vedotin 9 Bortezomib 9 Alemtuzumab 8 Dexamethasone 7 Methotrexate 6 Cytarabine 6 Busulfan 6 Carmustine 5 pembrolizumab 4 fludarabine 4 Vorinostat 4 Tacrolimus 4 Rituximab 4 Melphalan 4 Ifosfamide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, T-Cell, Peripheral × Salvage Therapy × Clear all

NCT07470996 2026-03-13

T-START-NR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡